Delta-like protein 3 (DLL3) is an inhibitory protein of Notch signaling that is involved in embryonic patterning and has been implicated in neuroendocrine cell development.1 DLL3 is typically located in the Golgi apparatus and cytoplasmic vesicles, where it inhibits Notch signaling by preventing the processing and cell surface expression of Notch.2

In high-grade neuroendocrine tumors—including small cell lung cancer (SCLC)—DLL3 is upregulated and expressed on the cell surface, with absent or rare expression on nonmalignant cells.1,3 This makes DLL3 an attractive potential target for investigating a BiTE® molecule aimed at neuroendocrine tumors, such as SCLC.

Learn more about modalities targeting DLL3:
BiTE® immunotherapy.

MCL video

Watch this video for an overview of the role of DLL3 in SCLC and the mechanism of action of a DLL3-targeted BiTE® molecule.

Download a factsheet that highlights the biology of DLL3 and its potential as a therapeutic target in SCLC and other neuroendocrine tumors.

Download an educational deck that overviews the unmet need in SCLC, T-cell engager technology, and the potential of DLL3 as a target for BiTE® Immunotherapy.


Search our clinical trials.

Visit our resources section for additional information on potential oncogenic targets.


1. Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Nat Rev Clin Oncol. 2017;14(9):549-561. 2. Chapman G, Sparrow DB, Kremmer E, Dunwoodie SL. Hum Mol Genet. 2011;20(5):905-916. doi:10.1093/hmg/ddq529. 3. Leonetti A, et al. Cell Oncol (Dordr). 2019;42:261-273.